title: [Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination].
abstract: This study was designed to evaluate the pharmacokinetics and toxicity of docetaxel administered via an intraperitoneal (i.p.) route for patients with gastric cancer. Eleven patients with peritoneal dissemination were entered into this trial. Patients were treated with 45 mg/m2 of i.p. docetaxel administration in 1 l of saline. Peak peritoneal concentration was 40.0 +/- 14.5 micrograms/ml and peritoneal concentration at 24 hours after drug administration was 4.3 +/- 3.9 micrograms/ml. The median pharmacokinetic advantage (AUC peritoneal/AUC plasma) was 515 (range 22-1, 770). Grade 2 and 3 toxicities included 5 episodes of diarrhea; 3 of abdominal pain; 3 of ascites; 2 of alopecia; and 1 of neutropenia. We conclude that intraperitoneal docetaxel administration is well tolerated and provides a peritoneal pharmacokinetic advantage for the treatment of peritoneal dissemination.
authors.affiliation: Division of Cancer Medicine, Graduate School of Medicine, Kanazawa University.
authors.forename: Sachio
authors.initials: S
authors.lastname: Fushida
authors.forename: Furui
authors.initials: F
authors.lastname: Nao
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kinami
authors.forename: Itasu
authors.initials: I
authors.lastname: Ninomiya
authors.forename: Takashi
authors.initials: T
authors.lastname: Fujimura
authors.forename: Genichi
authors.initials: G
authors.lastname: Nishimura
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Ohta
authors.forename: Koichi
authors.initials: K
authors.lastname: Yokogawa
authors.forename: Kenichi
authors.initials: K
authors.lastname: Miyamoto
authors.forename: Koichi
authors.initials: K
authors.lastname: Miwa
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D043823:Taxoids; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D016685:Mitomycin; D017239:Paclitaxel; D002945:Cisplatin; D014751:Vindesine